Gene Solutions Showcases MRD and Multi-Omics Innovations in Singapore

On October 15, 2025, at the Singapore Society of Oncology Annual Scientific Meeting 2025 (SSO ASM 2025), Gene Solutions presented groundbreaking advancements in Molecular Residual Disease (MRD) and AI-powered multi-omics technologies. The symposium, titled “Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors,” highlighted how these innovations are transforming cancer care from a reactive to a proactive model across the Asia-Pacific region.

Leading oncologists and molecular biology experts convened to explore the role of circulating tumor DNA (ctDNA) in MRD testing. This technology allows for monitoring cancer at a molecular level, offering insights that can significantly influence treatment strategies.

Scientific Insights and Advances

The discussions focused on how MRD assays analyze ctDNA in the blood, which aids in tracking cancer progression. Experts outlined several key benefits of this approach, including its potential to improve early detection of cancer recurrence and enhance personalized treatment plans.

Unlike traditional single-modality tests, Gene Solutions’ platform integrates DNA, RNA, and AI-enhanced multi-omics signals to deliver comprehensive tumor profiling. This multi-omics methodology not only enhances ctDNA sensitivity but also facilitates the detection of complex gene fusions and predicts primary tumor locations. Such advancements are critical for providing clinicians with deeper insights to make informed treatment decisions.

Recent studies published in JCO Oncology Advances and Nature’s npj Breast Cancer emphasize the potential of ctDNA-based MRD testing to predict early recurrence and establish cost-effective monitoring strategies in real-world scenarios. This research underscores the growing importance of genomic data in oncology.

Collaborative Efforts for Future Progress

Ida Deleskog Lindstroem, Global Medical Affairs Director at Gene Solutions, highlighted the significance of collaboration among healthcare professionals. She stated, “Molecular residual disease (MRD) and multi-omics platforms show promise in advancing precision oncology by enabling clinicians to detect cancer recurrence earlier and tailor treatments more effectively.” Lindstroem invited oncologists, researchers, and healthcare partners across the Asia-Pacific to engage in collaborative efforts to enhance these technologies.

With its CAP-accredited laboratory based in Singapore and a global operational network, Gene Solutions is committed to fostering scientific collaboration aimed at advancing genomic research and precision oncology across the region. The company has delivered over two million genetic tests and is recognized for its contributions to clinical studies and technology development.

For more information about the symposium and its highlights, visit Gene Solutions’ official website.

Gene Solutions continues to spearhead innovations in genetic testing and research, solidifying Singapore’s status as a hub for cutting-edge knowledge in the field of oncology.